Zydus Lifesciences rose 3% to an intra-day high of Rs 930 after the company received approval from the US FDA to manufacture ...

Zydus Lifesciences shares rose 8.34 per cent on March 19, touching an intraday high of Rs 910.30  at 1:00 PM when the company ...

Zydus Lifesciences Ltd has received final approval from the USFDA to manufacture 60 mg Apalutamide tablets for prostate ...

Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last ...

The company got the nod to manufacture and market apalutamide tablets, 60 mg, the generic equivalent of Erleada tablets, 60 ...

As per the IQVIA MAT January 2025 data, apalutamide tablets registered annual sales of $1099.80 million in the United States markets.

Zydus Lifesciences said that it has received final approval from the United States Food and Drug Administration (US FDA) to manufacture Apalutamide tablets, 60 mg.

Zydus Lifesciences Ltd. has received final nod from the United States Food and Drug Administration to manufacture 60 mg Apalutamide tablets, according to an exchange filing on Tuesday.

Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive ...

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Apalutamide Tablets, 60 mg (Erleada Tablets, 60 mg).

Zydus Lifesciences Ltd has received USFDA approval to manufacture a generic version of Apalutamide tablets for prostate cancer treatment. The 60 mg tablets will be produced in Ahmedabad, addressing a ...

The American Medical Association and more than two dozen other health organizations joined in an amicus brief encouraging the ...